{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:20:13Z","timestamp":1779297613673,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.dadr.2024.100233","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T07:52:23Z","timestamp":1712476343000},"page":"100233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Reduced emergency department use among insured individuals receiving extended-release buprenorphine in a health system setting"],"prefix":"10.1016","volume":"11","author":[{"given":"Bobbi Jo H.","family":"Yarborough","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott P.","family":"Stumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon L.","family":"Janoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Keast","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael C.","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah J.","family":"Leitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2024.100233_bib1","series-title":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder, 2020 Focused Update","author":"American Society of Addiction Medicine","year":"2020"},{"issue":"3","key":"10.1016\/j.dadr.2024.100233_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/JCP.0000000000001195","article-title":"Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-month safety, tolerability, and efficacy analysis","volume":"40","author":"Andorn","year":"2020","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.dadr.2024.100233_bib3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/ADM.0000000000001070","article-title":"Continued posttrial benefits of buprenorphine extended release: RECOVER study findings","volume":"17","author":"Boyett","year":"2023","journal-title":"J. Addict. Med."},{"issue":"5","key":"10.1016\/j.dadr.2024.100233_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/2045125314540297","article-title":"The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal","volume":"4","author":"Brissos","year":"2014","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.dadr.2024.100233_bib5","unstructured":"Canadian Agency for Drugs and Technologies in Health, 2019. Pharmacoeconomic Review Report: Buprenorphine Extended-release Injection (Sublocade). \u3008https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546358\/pdf\/Bookshelf_NBK546358.pdf\u3009\u00a0(Accessed 3\/31\/2024)."},{"issue":"6","key":"10.1016\/j.dadr.2024.100233_bib6","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"10","key":"10.1016\/j.dadr.2024.100233_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa022164","article-title":"Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone","volume":"349","author":"Fudala","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"10173","key":"10.1016\/j.dadr.2024.100233_bib8","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.dadr.2024.100233_bib9","article-title":"Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic","volume":"209183","author":"Heil","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"issue":"4","key":"10.1016\/j.dadr.2024.100233_bib10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3947\/ic.2021.0136","article-title":"Long-acting injectable antiretroviral agents for HIV treatment and prevention","volume":"53","author":"Kim","year":"2021","journal-title":"Infect. Chemother."},{"issue":"6","key":"10.1016\/j.dadr.2024.100233_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.9740\/mhc.2019.11.392","article-title":"Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans","volume":"9","author":"Leighty","year":"2019","journal-title":"Ment. Health Clin."},{"issue":"5","key":"10.1016\/j.dadr.2024.100233_bib12","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1097\/ADM.0000000000000647","article-title":"Recovery from opioid use disorder (OUD) after monthly long-acting buprenorphine treatment: 12-month longitudinal outcomes from RECOVER, an observational study","volume":"14","author":"Ling","year":"2020","journal-title":"J. Addict. Med."},{"issue":"6","key":"10.1016\/j.dadr.2024.100233_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study","volume":"13","author":"Ling","year":"2019","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.dadr.2024.100233_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.11.004","article-title":"Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study","volume":"110","author":"Ling","year":"2020","journal-title":"J. Subst. Abus. Treat."},{"issue":"6","key":"10.1016\/j.dadr.2024.100233_bib15","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern. Med."},{"issue":"10","key":"10.1016\/j.dadr.2024.100233_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067194","article-title":"Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation","volume":"12","author":"Lowry","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.dadr.2024.100233_bib17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1186\/s13063-022-06595-0","article-title":"Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone","volume":"23","author":"Marsden","year":"2022","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.dadr.2024.100233_bib18","first-page":"Cd011117","article-title":"Opioid agonist treatment for people who are dependent on pharmaceutical opioids","volume":"9","author":"Nielsen","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.dadr.2024.100233_bib19","article-title":"18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: integrated analysis of phase 3 studies","volume":"154","author":"Rutrick","year":"2023","journal-title":"J. Subst. Use Addict. Treat."},{"issue":"6","key":"10.1016\/j.dadr.2024.100233_bib20","first-page":"22","article-title":"Extended release drug delivery strategies in psychiatry: theory to practice","volume":"2","author":"Siegel","year":"2005","journal-title":"Psychiatry"},{"key":"10.1016\/j.dadr.2024.100233_bib21","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.dadr.2024.100233_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.drugalcdep.2016.07.024","article-title":"Understanding opioid overdose characteristics involving prescription and illicit opioids: a mixed methods analysis","volume":"167","author":"Yarborough","year":"2016","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.dadr.2024.100233_bib23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.drugalcdep.2015.12.031","article-title":"Methadone, buprenorphine and preferences for opioid agonist treatment: a qualitative analysis","volume":"160","author":"Yarborough","year":"2016","journal-title":"Drug Alcohol Depend."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724624000179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T07:13:16Z","timestamp":1718867596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724624000179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":23,"alternative-id":["S2772724624000179"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100233","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced emergency department use among insured individuals receiving extended-release buprenorphine in a health system setting","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2024.100233","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100233"}}